DaVita Inc.
DVADaVita is a cash-generating healthcare utility built around life-sustaining dialysis treatments.
Because in dialysis, scale, regulation, and demographics decide who survives and who thrives.
Business Model
Clinic-based dialysis care
Operates dialysis centers and gets paid mainly by government and private insurers per treatment.
Economic Engine
Recurring medical necessity
Patients need treatments several times a week, creating steady, predictable revenue.
Long-Term Lens
Reimbursement durability
Long-term value depends on stable government payment rates and cost control.
On this page
Company Story
How do DaVita Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A scale-driven dialysis franchise with steady demand and strong cash flow, but long-term returns hinge on reimbursement stability and smart capital allocation.”
What does DaVita Inc. actually do?
DaVita operates dialysis centers that treat patients with kidney failure.
- Runs a large network of outpatient dialysis clinics.
- Provides life-sustaining blood filtration treatments multiple times per week.
- Employs about 76,000 people including nurses, technicians, and clinical staff.
Why it matters
Dialysis is not optional
Patients with end-stage kidney disease require regular treatment to survive, making demand steady and recurring.
How does DaVita Inc. make money?
DaVita gets paid per dialysis treatment, mainly by government programs and private insurers.
- Bills Medicare and other government programs for a large share of treatments.
- Receives higher reimbursement rates from private insurers for some patients.
- Manages costs across clinics to earn an operating margin of about 14.7%.
Economic clue
Strong cash conversion
Free cash flow is about 1.75 times net income, showing reported profits turn into real cash.
Why do long-term investors keep DaVita Inc. on the radar?
DaVita sits at the center of a growing, aging population that needs ongoing kidney care.
- Revenue has grown about 4.1% per year on average over five years.
- Dialysis demand is tied to aging and chronic diseases like diabetes.
- The company repurchased about $1.8 billion of stock in the last 12 months.
Investor takeaway
Utility-like cash flows
A 9.6% free cash flow margin supports buybacks and long-term compounding if reimbursement remains stable.
Based on company financial statements.
Benchmark Comparison
How has DaVita Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$1,428
+42.8% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| DVA | +42.8% | $1,428 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame DaVita Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to essential healthcare services with recurring demand.
- A business that converts accounting earnings into strong free cash flow.
- Aggressive share buybacks instead of dividends.
Be Careful If You Expect
- Fast revenue growth, five-year average growth is about 4.1%.
- Expanding profit margins, margins have been contracting.
- Low regulatory risk, government reimbursement is central to the model.
What To Watch Over Time
- Changes in Medicare reimbursement rates for dialysis treatments.
- Mix between private insurance and government payers.
- Trends in operating margin, currently about 14.7%, and net margin at 5.5%.
Key Metrics
Which metrics matter most for DaVita Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
4.1% average annual growth over 5 years
1.1% average annual growth over 5 years
27.0% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 4.1% average annual growth over 5 years | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 1.1% average annual growth over 5 years | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 27.0% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do DaVita Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
10.8% ROIC
27.0% gross margin
9.6% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 10.8% ROIC | The business is currently showing fair capital efficiency. |
| Profitability | 27.0% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 9.6% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold DaVita Inc.?
DaVita Inc. currently appears in these ETF and fund proxies.
IWB
iShares Russell 1000 ETF
SPY
SPDR S&P 500 ETF Trust
Questions & Answers
What questions come up most often about DaVita Inc.?
Company-specific questions readers often ask about DaVita Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
DaVita operates dialysis clinics that provide life-sustaining treatments to patients with kidney failure.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Dialysis is life-sustaining and recurring, patients typically require treatment three times a week, creating durable demand that is not tied to economic cycles.
Scale advantages allow DaVita to spread overhead across a vast clinic network, negotiate supply contracts, and manage staffing more efficiently than smaller rivals.
An aging population and rising chronic disease rates support steady patient growth over decades.
Strong cash conversion, with free cash flow about 1.75 times net income, gives management flexibility to repurchase shares and compound per-share value.
Bear case
What can break
Government reimbursement pressure could compress margins further, since a large share of revenue depends on Medicare payment rates.
Home dialysis or new treatment technologies could reduce the need for in-center treatments, weakening the traditional clinic model.
Persistent labor shortages or wage inflation could erode the already modest 5.5% net margin.
Political or regulatory reforms targeting private insurer pricing could reduce the higher-margin commercial patient mix.
Risk Radar
Key Risks
Where downside pressure can build.
Reimbursement risk: A large portion of revenue comes from government programs, so even small percentage cuts to payment rates could materially reduce the 14.7% operating margin.
Margin compression: Net margin is only 5.5%, leaving limited cushion against wage or supply cost increases.
Payer mix risk: Profitability depends partly on higher-paying private insurance patients relative to government-insured patients.
Pressure points
Concentration risk
A significant portion of revenue is tied to U.S. government reimbursement for dialysis treatments, making the company highly exposed to policy and payment rate changes in one country.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $150.76
- Daily move
- +0.55%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.